RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)
Closed Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- 75A50126R00002
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Washington, District of Columbia 20024, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (BARDA) seeks late-stage clinical development, FDA regulatory approval, and procurement of 2-PAM (Pralidoxime) autoinjectors as a drug/device combination product to treat organophosphate poisoning and nerve agents in adult and pediatric populations, with proposals due July 30, 2026.
Place of performance is Washington, DC. The procurement is unclassified and carries no set-aside. The base period is 36 months (2026–2029) with optional periods extending through 2034 for a total contract value up to 96 months. The base contract combines one Cost-Plus-Fixed-Fee (CPFF) CLIN (0001) for development activities and one Firm-Fixed-Price (FFP) CLIN (0002) for procurement of 500,000 adult-dose autoinjectors. Option periods include additional CPFF CLINs (0003, 0005) for post-market commitments and FFP CLINs (0004, 0006, 0007) for procurement of 1,500,000 additional autoinjectors, targeting approximately 2,000,000 total units for the SNS/CHEMPACK Program.
The product must achieve FDA approval or Emergency Use Authorization with minimum three-year stability and demonstrate 99.999% reliability per FDA guidance. Offerors must be registered in SAM and provide facility security plans for procurement-related subcontractors. The Final Security Plan is due 90 days post-award; the Quality Management System Plan is due 30 days post-award. Past performance may include non-government contracts deemed relevant to the effort. Long lead-time items such as glass cartridges and active pharmaceutical ingredients should include risk mitigation strategies. Small business subcontracting plans are required for offerors that are not small businesses. The Contracting Officer is Erin Greninger (erin.greninger@hhs.gov; 771-210-7767). NAICS 541714; PSC AB12. All questions must be submitted by July 15, 2026.
Notice text
BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.
Files
| File | Type | Posted |
|---|---|---|
| 75A50126R00002 Amend 0001.pdf | ||
| 75A50126R00002 Amendment 0001.pdf | ||
| 06 RFP_PBS_2PAM_2026_Final.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| RFP - 2-PAM Autoinjectors for Project Bioshield (PBS) | Award Notice | |
| This notice | Solicitation | |
| 2-PAM Autoinjectors Project Bioshield | Pre-Solicitation |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity